EDGEWISE THERAPEUTICS INC's ticker is EWTX and the CUSIP is 28036F105. A total of 49 filers reported holding EDGEWISE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $4,378,195 | -29.0% | 243,098 | -28.1% | 0.00% | -50.0% |
| Q1 2024 | $6,165,193 | +267.6% | 338,004 | +120.5% | 0.00% | +100.0% |
| Q4 2023 | $1,677,015 | +91.9% | 153,292 | +0.5% | 0.00% | – |
| Q3 2023 | $873,745 | -26.6% | 152,486 | -0.7% | 0.00% | – |
| Q2 2023 | $1,189,640 | +182080.7% | 153,502 | +56.9% | 0.00% | – |
| Q1 2023 | $653 | -31.6% | 97,824 | -8.3% | 0.00% | – |
| Q4 2022 | $954 | -99.9% | 106,702 | -4.4% | 0.00% | – |
| Q3 2022 | $1,099,000 | +20.8% | 111,609 | -2.4% | 0.00% | – |
| Q2 2022 | $910,000 | -20.7% | 114,337 | +3.8% | 0.00% | – |
| Q1 2022 | $1,148,000 | -36.3% | 110,115 | +18.0% | 0.00% | -100.0% |
| Q4 2021 | $1,801,000 | +259.5% | 93,350 | +222.3% | 0.00% | – |
| Q3 2021 | $501,000 | -49.8% | 28,963 | -38.2% | 0.00% | – |
| Q2 2021 | $999,000 | – | 46,840 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,553,661 | $27,981,435 | 34.02% |
| Novo Holdings A/S | 6,344,430 | $114,263,184 | 6.63% |
| Orbimed Advisors | 15,021,721 | $270,541,195 | 5.34% |
| TCG Crossover Management, LLC | 2,272,728 | $40,931,831 | 4.27% |
| Frazier Life Sciences Management, L.P. | 3,731,067 | $67,196,517 | 3.14% |
| Cormorant Asset Management, LP | 3,006,534 | $54,147,677 | 3.13% |
| Opaleye Management Inc. | 580,000 | $10,445,800 | 2.39% |
| RA Capital Management | 8,909,091 | $160,452,729 | 2.12% |
| VR Adviser, LLC | 1,818,182 | $32,745,458 | 2.08% |
| MPM BioImpact LLC | 740,661 | $13,339,305 | 2.07% |